Page last updated: 2024-11-03

risperidone and Central Nervous System Diseases

risperidone has been researched along with Central Nervous System Diseases in 2 studies

Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.

Central Nervous System Diseases: Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord.

Research Excerpts

ExcerptRelevanceReference
" The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only)."4.80Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. ( , 1998)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kamijo, Y1

Reviews

2 reviews available for risperidone and Central Nervous System Diseases

ArticleYear
[Dangerous drugs: products containing synthetic chemicals].
    Nihon rinsho. Japanese journal of clinical medicine, 2016, Volume: 74, Issue:2

    Topics: Alkaloids; Antipsychotic Agents; Cannabinoids; Central Nervous System Diseases; Consciousness Disord

2016
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
    The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 12

    Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Central Nervous Syst

1998